Nektar Therapeutics

Novartis Ag

Inhale Therapeutic Systems, Inc.

Novartis Pharma Ag

David B Bennett

Kirsten M Cabot

Hi-Shi Chiang

John S Patton

Robert M Platz

Bing Yang

Cynthia L Stevenson

Thomas K Brewer

David D Lesikar

Jayne E Hastedt

David K Gong

David Lechuga-Ballesteros

Linda C Foster

Herman E Snyder

Ronald Keith Wolff

Benjamin Lee Hughes

Herman Snyder

Geraldine Venthoye

Darrel LaVern Allen

Cheryl L M Stults

Mary Stiff-Torvik

William David Roeder

Russ Lehrman

S Russ Lehrman

Trixie K Tan

Sudha Nagarajan

Joanne Greene

The present invention provides exemplary systems and methods for producing dry powder formulations. In one embodiment, a system () includes at least one conditioning zone () having an inlet () to introduce an atomized formulation () into the conditioning zone. A controller () controls temperature and relative humidity of the airflow into the conditioning zone to allow amorphous-to-crystalline transformation of the atomized formulation. In another embodiment, the formulation is suspended in the conditioning zone for a residence time of sufficient duration to allow surface orientation of surface active components. A dryer () is coupled to the conditioning zone to dry the atomized formulation, and a collector () collects the formulation in powder form.

Spray drying process control of drying kinetics

Provided are stabilized follicle stimulating protein (FSP) dry powder compositions for aerosolized delivery to the deep lung, methods of preparing and administering such compositions, and methods for treating infertility involving administering the dry powders by pulmonary delivery to the deep lung.

Pulmonary administration of dry powder formulations for treating infertility

The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 &#x3b1;-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).

Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation

The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 &agr;-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).

This invention relates to novel, liquid crystal forms of the cyclic peptide cyclosporin and to novel powder formulations of cyclosporin prepared using this novel liquid crystal form of the drug. Methods for preparing and using these formulations are also provided. In particular, the present invention relates to dispersible spray dried particles of cyclosporin suitable for pulmonary delivery.

Liquid crystal forms of cyclosporin

Growing community of inventors

San Jose, CA, United States of America

David B Bennett